MOTS-c: Common Questions and What the Literature Says

MOTS-c (mitochondrial open reading frame of the twelve S rRNA type-c) is a mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA gene. Most of the questions asked about it online concern practical administration details: time of day, fasted versus fed state, and how long an interval should separate administration from food. This page answers those questions the only defensible way — by describing what the published literature actually contains and stating plainly where no study exists. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision.

What MOTS-c Is in the Published Literature

The peptide was characterised in a 2015 report in Cell Metabolism, in which researchers described MOTS-c as encoded in the mitochondrial 12S rRNA, targeting skeletal muscle, inhibiting the folate cycle and its tethered de novo purine biosynthesis, leading to AICAR accumulation and AMPK activation, with the study reporting that MOTS-c prevented diet-induced obesity and insulin resistance in mice (PMID 25738459). A 2023 review in Frontiers in Endocrinology summarised the peptide as a stress-responsive regulator of metabolic homeostasis with reported roles across metabolism, exercise physiology and age-related disease, and framed it as a candidate for therapeutic exploitation rather than an established therapy (PMID 36761202).

Subsequent mechanistic work has added molecular detail. A 2024 iScience study reported that MOTS-c modulated skeletal muscle function by directly binding and activating casein kinase 2 (CK2) (PMID 39559755). A 2022 paper in Peptides reported that MOTS-c promoted muscle differentiation in vitro, that is, in cultured cells rather than in living animals (PMID 35842023). A 2025 study in Redox Biology reported that MOTS-c attenuated lung ischemia-reperfusion injury through MYH9-dependent nuclear translocation and transcriptional activation of antioxidant genes (PMID 40403491).

Is There a "Best Time of Day" in the Studies?

No. Across the located literature there is no study that compared morning with evening administration of MOTS-c, no study that randomised animals or humans to different clock times, and no chronotherapy or circadian-dosing analysis of the peptide. The 2015 characterisation study addressed metabolic outcomes in mice and the molecular pathway involved, not administration schedules (PMID 25738459). The 2023 review, which surveyed the field broadly, described biological roles and therapeutic possibilities rather than any timing protocol (PMID 36761202).

This matters because an "AM versus PM" answer would require a head-to-head comparison with matched outcomes. No such comparison appears in the verified literature for MOTS-c. Any timing claim circulating elsewhere is therefore not traceable to a published MOTS-c study, and this page does not supply one.

Why circadian biology does not substitute for a timing study

Mitochondrial function, AMPK signalling and substrate use all vary over a 24-hour cycle in general physiology, and the 2023 review discussed MOTS-c in the context of metabolic and exercise-related stress responses (PMID 36761202). Plausible mechanism is not evidence of a timing effect. Extrapolating from "AMPK is circadian" to "a given hour is better" is inference, not a reported finding, and the distinction is the whole point of reading primary literature.

Fasted Versus Fed: What Studies Report

No located study compared administration in a fasted state with administration after food, in animals or in humans. Two features of the literature explain why this question has no experimental answer.

• The studies are preclinical. The reported models include diet-induced obese mice (PMID 25738459), immobilisation-induced skeletal muscle atrophy, where researchers reported that MOTS-c attenuated atrophy by suppressing lipid infiltration (PMID 38170165), and cultured myoblasts (PMID 35842023). Rodents fed ad libitum and cells in culture medium do not model a human meal schedule.
• Administration in these models was parenteral or in vitro. Peptides delivered by injection or added to culture medium do not traverse the gastrointestinal tract, so the fed-state variables that matter for oral drugs — gastric emptying, food-drug binding, first-pass metabolism — were not the experimental question in these reports.

One recurring source of confusion is that metabolic studies frequently measure fasting glucose or perform fasting-based tolerance testing. For example, researchers reported that MOTS-c relieved hyperglycemia and insulin resistance in a model of gestational diabetes mellitus (PMID 34798268), and a 2025 report in Experimental & Molecular Medicine described MOTS-c preventing pancreatic islet cell senescence to delay diabetes (PMID 40855115). Fasting in such work is a measurement condition used to standardise glucose readings, not an instruction about when the peptide was administered. Reading a fasting assay as a fasting protocol is a misreading of the methods.

How Long Before Eating? Where the Literature Is Silent

There is no published MOTS-c study that tested an interval between administration and food intake — not 15 minutes, not an hour, not any duration. No pharmacokinetic study in the verified set characterised absorption relative to meals, and no outcome study varied meal timing as an experimental variable. The honest answer is that the number does not exist in the literature, and any specific waiting period quoted online is unsourced with respect to MOTS-c research.

What the Studies Did Examine

The table below summarises the reported focus of each verified paper. It is a map of the evidence base, which is overwhelmingly mechanistic and preclinical.

Read as a whole, the literature is a biology literature. It describes pathways — AMPK, CK2, Nrf2, MYH9-linked nuclear signalling — and disease models in animals and cells. It is not a literature of human dose-finding, schedule comparison or meal-timing pharmacology.

MOTS-c Adverse Events: What Studies Report

The verified papers are mechanistic and preclinical, and adverse-event reporting was not their primary outcome. No human safety trial of administered MOTS-c appears in this set, so there is no published human adverse-event profile, no tolerability table and no long-term safety follow-up to summarise. The 2023 review discussed MOTS-c as a peptide of therapeutic interest still under investigation rather than an agent with an established clinical safety record (PMID 36761202).

Two further points are worth noting for anyone reading the literature critically. First, several reports describe MOTS-c influencing cell survival and proliferation pathways in disease models, including cancer biology, where researchers reported suppression of ovarian cancer progression through a specific deubiquitination mechanism (PMID 39321430); findings in one tumour model do not generalise to other tissues or to healthy organisms. Second, effects reported in immobilised or injured animals, such as the atrophy model in which researchers reported reduced lipid infiltration (PMID 38170165), describe responses in a pathological state and say nothing about outcomes in unaffected physiology.

Regulatory Context

MOTS-c is not an approved drug product. Material sold or supplied for laboratory work is typically labelled research use only (RUO), meaning it is intended for in vitro or preclinical investigation and is not qualified for human use. That regulatory status is consistent with the shape of the evidence described above: the peptide has been studied as a research molecule, and the 2023 review characterised it as a candidate for future therapeutic exploitation rather than a clinically established treatment (PMID 36761202).

What Would Actually Answer the Timing Questions

For the record, the study designs that would be needed do not currently exist for MOTS-c in the verified literature:

1. Human pharmacokinetics. Plasma concentration-time curves after administration, with and without food, would be required before any statement about meal intervals could be evidence-based.
2. Randomised schedule comparison. A trial assigning participants to morning versus evening administration with identical outcome measures would be required before "AM or PM" had an answer.
3. Fed-state comparison. A design in which the same administration occurred in fasted and postprandial states, with matched endpoints, would be required to address fasting questions.
4. Replication in humans of preclinical endpoints. Metabolic effects reported in mice, such as the prevention of diet-induced insulin resistance in the 2015 study (PMID 25738459), would need testing in controlled human trials before human relevance could be assumed.

Until such work is published, the accurate summary is short: the literature describes MOTS-c biology in animals and cells in some mechanistic detail, and describes nothing about clock time, fasting state or meal intervals in humans. Where a question has no study behind it, the absence of evidence is the finding, and this page reports it as such rather than filling the gap with inference.

References

• MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation (Frontiers in Endocrinology, 2023)
• The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (Cell Metabolism, 2015)
• MOTS-c modulates skeletal muscle function by directly binding and activating CK2 (iScience, 2024)
• Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination (Advanced Science, 2024)
• Mitochondrial-derived microprotein MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration (American Journal of Physiology. Endocrinology and Metabolism, 2024)
• The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus (Pharmacological Research, 2022)
• Pyrroloquinoline Quinone Alleviates Mitochondria Damage in Radiation-Induced Lung Injury in a MOTS-c-Dependent Manner (Journal of Agricultural and Food Chemistry, 2024)
• Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes (Experimental & Molecular Medicine, 2025)
• Novel function of MOTS-c in mitochondrial remodelling contributes to its antiviral role during HBV infection (Gut, 2024)
• MOTS-c promotes muscle differentiation in vitro (Peptides, 2022)
• MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-dependent nuclear translocation and transcriptional activation of antioxidant genes (Redox Biology, 2025)
• MOTS-c attenuates mitochondrial dysfunction induces pyroptosis and cartilage degradation in osteoarthritis via an Nrf2-Dependent Mechanism (Free Radical Biology & Medicine, 2025)